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Background: High on-treatment ADP platelet reactivity (HPR) measured by VerifyNow
P2Y12 assay (VN) is an established risk factor for ischemic events after percutaneous
coronary intervention (PCI). We hypothesized that routine use of VN at time of PCI in
clinical practice may affect choice of P2Y12 antiplatelet therapy at discharge.
Methods: In a single center retrospective analysis, we examined the influence of VN
testing on choice of P2Y12 inhibitor post PCI in routine clinical practice. Assessment
of HPR was used routinely in clinical care during the time period of analysis at
discretion of clinical providers. Subjects with PRU>208 after the loading dose of
clopidogrel or during clopidogrel steady state were switched to alternate P2Y12
inhibitors.
Results: We identified 1001 patients with PCI during the time period specified. A total
of 252 subjects underwent VN testing. Among those, 43% were found to have HPR on
clopidogrel and were switched to alternate therapies (prasugrel [n=60], ticagrelor
[n=48]). Patients who had VN platelet function testing were more likely to be dis-
charged on clopidogrel as compared to those who did not have VN assay done (57% vs.
50%, p=0.039). There was no significant difference in 1-year net-MACE (CVD, MI,
stent thrombosis, BARC 2 or higher bleeding) using tailored antiplatelet therapy (VN
testing) as compared to standard of care group (adjusted HR:0.92, 95% CI: 0.54–1.5,
p=0.74).
Conclusion: Routine use of VN assay in personalized antiplatelet treatment decision-
making after PCI is associated with lower likelihood of using novel P2Y12 inhibitors.
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Introduction
Among available P2Y12 platelet inhibitors, clopidogrel continues to be widely used
because of the decreased risk of bleeding, lower cost, and less likelihood of side
effects such as dyspnea. Clopidogrel bioactivation is in part determined by inter-
individual differences in pharmacogenetics, predominantly cytochrome P450 2C19
variants.1,2 Inadequate platelet inhibition increases risk of stent thrombosis and
other adverse cardiovascular events.3
High on treatment platelet reactivity (HPR) during treatment with clopidogrel
has been consistently found to be strong risk factor for recurrent ischemic events
after PCI.4,5 In the landmark study by Stone et al, HPR defined as PRU>208
measured by the VN P2Y12 assay, was associated with 2.49 fold increased risk
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of stent thrombosis after PCI.6 Insufficient P2Y12 receptor
inhibition contributes to the HPR measured by the VN
assay.7 The superiority of prospective platelet reactivity
testing and adaptation of antiplatelet therapy based on
VN P2Y12 assay in comparison to standard has been
questioned after negative clinical trial results.8–10
However the TROPICAL-ACS study conducted by
Sibbing et al demonstrated the benefit of antiplatelet test-
ing to guide de-escalation of P2Y12 inhibition by reduc-
tion of combined bet ischemic and hemorrhagic endpoint
(net-MACE).11
Applied in clinical practice, patients with HPR by VN
assay are routinely switched to novel, more potent P2Y12
inhibitors prasugrel or ticagrelor due to concerns about
increased risk of stent thrombosis due to inadequate plate-
let inhibition.
We intended to examine the impact of routine platelet
monitoring with VN assay on choice of antiplatelet ther-
apy in patients undergoing PCI, and hypothesized that
the use of VN platelet function testing will result in higher
use of clopidogrel compared to standard of care without
the use of platelet function testing.
Materials and Methods
Study Objective
This was a retrospective, observational study to deter-
mine the influence of routine use of P2Y12 platelet
function assay testing by VerifyNow (VN) on tailoring
antiplatelet therapy in patients after PCI. Indiana
University Institutional Review Board approval was
obtained for the study. Requirement for individual writ-
ten informed consent for participation in the research
study was waived by the Indiana University Institutional
Review Board due to the retrospective, observational
design of the study. Confidentiality of patient level
data was maintained and analysis was performed on
a de-identified data set. The study was in compliance
with the Declaration of Helsinki.
Patient Population
The study population consisted of 1001 patients who
had undergone PCI with subsequent placement of at
least 1 drug eluting (DES) or bare metal stent (BMS)
between 2012 and 2018 at Eskenazi hospital in
Indianapolis. Platelet reactivity testing with VN P2Y12
assay was available bedside in the cardiac catheteriza-
tion laboratory at the discretion of the clinical provider
at Eskenazi Health during this time period. When used,
VN P2Y12 assay was completed after administration of
clopidogrel (at least 4 hrs after 600mg loading dose if
not loaded previously), usually at the time of PCI.
Pharmacogenetic testing was not routinely performed
in our institution during the study period.
Study Design
Platelet reactivity was assessed using VN P2Y12 assay
according to the manufacturer’s instructions. The VN
point-of-care instrument measures platelet-induced
aggregation of fibrinogen coated beads in response to
20µM ADP as an increase in light transmittance and
uses a proprietary algorithm to report values in P2Y12
reaction units (PRU).12 The assay also contains prosta-
glandin E1 to minimize contribution of P2Y1 to platelet
aggregation. HPR was defined as PRU>208 to maintain
consistency with previous studies.6 Providers had been
instructed on the use of the PRU cutoffs and were encour-
aged to continue patients on clopidogrel if they had low
on treatment platelet reactivity. Patients identified with
HPR (PRU>208) after administration of clopidogrel were
switched to either prasugrel or ticagrelor. Percutaneous
coronary interventions were performed according to
established standards and guidelines.13 Subjects who
had VN testing done were compared to subjects who
did not have a platelet assay performed during their
hospital stay at Eskenazi Health between 2012 and
2018. During the time period analyzed, we did not follow
a protocol of de-escalation as used in the TROPICAL-
ACS study with repeat platelet testing on clopidogrel 1
week after switching from prasugrel.11
The primary outcome of the study was the prevalence of
clopidogrel prescribed at hospital discharge. The main clin-
ical endpoint was defined as combined net-MACE (cardio-
vascular death, MI, stent thrombosis, bleeding in Academic
Research Consortium [BARC] 2 or higher bleeding)
assessed at 1 year.14–16 Endpoints were evaluated by review
of electronic medical records. Patients with stent thrombo-
sis and cardiovascular deaths were further adjudicated using
original source documents and angiographic images when
available. Death was considered non-cardiac when an
unequivocal non-cardiac cause was documented.
Statistical Analysis
Baseline variables were compared between groups using
Pearson-Chi Square test, and continuous data by Student’s
t-test. Binary outcome was compared by use of one-sided
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Fisher’s exact test. Survival analysis was performed using
Kaplan-Meier estimates and the Log rank test was used to
evaluate differences between groups. Cox proportional
hazards model regression analysis was performed with
forward multivariate adjustment of clinically significant base-
line co-variates (p<0.1). Statistical analysis was performed
with the use of SPSS software, version 25.0 (SPSS Inc.,
Chicago, Illinois).
Table 1 Clinical Variables
Characteristics VerifyNow P2Y12 Platelet Assay
Was Not Done (n = 749)
VerifyNow P2Y12 Platelet
Assay Was Done (n = 252)
p value*
Age (years) 61.7 ± 11 60.9 ± 10 0.33
Gender 0.17
Female 264/749 (35%) 101/252(40%)
Male 485/749 (65%) 151/252 (60%)
Race 0.73
Black or African American 270/749 (36%) 93/252 (37%)
White 400/749 (53%) 130/252 (52%)
Unknown/Not reported 60/749 (8%) 24/252 (9%)
Body mass index (kg/m2) 31.8 ± 8 32 ± 8 0.75
Angina 0.14
Stable 149/749 (20%) 65/252 (26%)
Unstable 316/749 (42%) 100/252 (40%)
Acute MI on Presentation <0.001
STEMI 170/749 (23%) 16/252 (6%)
NSTEMI 321/749 (43%) 173/252 (69%)
Medical History
Diabetes mellitus 343/749 (46%) 121/252 (48%) 0.54
Hypertension 563/749 (75%) 217/252 (86%) <0.001
End stage renal disease 11/749 (1%) 6/252 (2%) 0.33
Hyperlipidemia 312/749 (42%) 130/252 (52%) 0.006
Peripheral vascular disease 53/749 (7%) 21/252 (8%) 0.51
Cerebrovascular accident 67/749 (9%) 32/252 (13%) 0.08
Prior myocardial infarction 107/749 (14%) 52/252 (21%) 0.17
Coronary artery bypass graft 79/749 (10%) 31/252 (12%) 0.44
Prior percutaneous coronary intervention 127/749 (17%) 69/252 (27%) <0.001
Tobacco use 495/749 (66%) 177/252 (70%) 0.23
Stent Type <0.001
Drug eluting stent 628/749 (84%) 234/252 (93%)
Bare metal stent 121/749 (16%) 17/252 (7%)
Medication at Discharge
ACEi/ARB 585/749 (78%) 204/252 (81%) 0.34
Aspirin 729/749 (97%) 244/252 (97%) 0.67
Statin 724/749 (97%) 245/252 (97%) 0.66
Beta blocker 688/749 (92%) 240/252 (95%) 0.074
Proton pump inhibitor 145/749 (19%) 67/252 (27%) 0.015
P2Y12 Inhibitor Pre-VN
Clopidogrel 241/252 (96%)
Prasugrel 8/252 (3%)
Ticagrelor 3/252 (1%)
Notes: *t-test (continuous data), Chi-square (Binary data).
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Results
A total of 1001 patients had PCI performed between 2012
and 2018. Among those, 252 had VN platelet function
assay performed during their hospital stay. The majority
of patients (96%) who had VN platelet testing performed
had received pre-treatment with clopidogrel. Patients who
did not have VN platelet reactivity testing performed were
more likely to have presented with ST elevation myocar-
dial infarction (STEMI) and to have a bare metal stent
placed. Patients who did have VN platelet testing done
were more likely to have a prior diagnosis of hypertension,
hyperlipidemia, or prior PCI, present with a non-STEMI,
and were more likely to be prescribed a proton-pump
inhibitor (Table 1). Clinical baseline variables were other-
wise well matched between groups.
Among patients who underwent platelet reactivity
testing, 43% were found to be non-responders and
were switched to alternate therapies (prasugrel [n=60],
ticagrelor [n=48]). There was a wide range of on-
treatment platelet reactivity (mean ± SD: 178 ± 88
PRU; range: 4–385 PRU).
Patients undergoing platelet function assay testing
using VN were more likely to be discharged on clopido-
grel vs. an alternate P2Y12 inhibitor in comparison to
those who did not have this test done (57% vs. 50%,
p=0.039) (Figure 1).
Use of VN in tailoring antiplatelet therapy after PCI
compared to standard of care group was associated
with no significant difference in risk of recurrent
1-year net-MACE (CVD, MI, stent thrombosis, BARC
2 or higher bleeding) (non-adjusted Hazard Ratio: 0.96
[95% CI: 0.57–1.6],[p=0.87]). There were no signifi-
cant differences in clinical outcomes after multivariate
adjustment comparing VN platelet reactivity testing
group vs. standard of care (no VN) group (Table 2,
Figure 2).
Discussion
The results of our retrospective analysis demonstrate that
routine use of VN assay in personalized antiplatelet treat-
ment decision-making after PCI is associated with lower
likelihood of using novel P2Y12 inhibitors as compared to
standard treatment. Despite the higher prevalence of sub-
jects with prior PCI and higher prevalence of NSTEMI in
patients among the guided therapy group, there was no
significant difference in clinical outcomes during 1-year
follow up. Patients presenting with acute ST-elevation
myocardial infarction were almost universally treated
with either prasugrel or ticagrelor at time of primary
PCI, making it unfeasible to use VN guidance for clopido-
grel response at time of initial hospitalization. Upfront use
of a novel P2Y12 inhibitor in our practice was routinely
continued until discharge, and de-escalation of antiplatelet
therapy using a platelet assay was not performed as
a strategy in our institution.
Routine antiplatelet monitoring for high on-treatment
platelet reactivity has been controversial due to lack of
prospective trials showing superiority of such an approach
compared to universal use of either prasugrel or
ticagrelor.8–10 However the main focus of use in our prac-
tice was to reduce the use of more expensive novel P2Y12
inhibitors while minimizing the risk of thrombotic events
by screening for HPR on clopidogrel in the periprocedural
period. More recently the TROPICAL-ACS trial showed
benefit of guided antiplatelet de-escalation after PCI using
the multiplate assay.11 In that trial, patients who demon-
strated low platelet reactivity after 7 days of clopidogrel
14 days post PCI, were switched to clopidogrel, whereas
patients with HPR continued on prasugrel. The net-MACE
benefit was driven mainly by a lower incidence of bleed-
ing events, but also lower risk of combined ischemic
endpoints.11 In contrast, in the much smaller study by
Cayla et al VN guided change of antiplatelet therapy in
elderly patients who were initially prescribed low dose
prasugrel was not superior to continued treatment with
prasugrel 5mg daily.17
While clinical practice guidelines recommend the use
of either ticagrelor or prasugrel over clopidogrel after PCI
in patients presenting with ACS, more recent clinical trials
have highlighted the increased risk of non-CABG bleeding
with universal use of a potent P2Y12 inhibitor.18–20
Avoidance of a potent P2Y12 inhibitor in patients who
378 
(50%)
144
(57%)60 
(24%)
48 
(19%)
221
(30%)
150
(20%)
n=749 n=252
Platelet Testing Performed?
Figure 1 Distribution of different P2Y12 inhibitors prescribed at time of discharge
for groups with and without VerifyNow (VN) platelet function testing.
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have an acceptable pharmacodynamic response to clopido-
grel and who may be at increased risk of bleeding may be
a preferred strategy in post PCI dual antiplatelet therapy.
Clinical risk scores have been developed to estimate bleed-
ing risk on prolonged dual antiplatelet therapy, however
they lack specificity and sensitivity and are less useful in
assessing risk in regard to choice of potency of antiplatelet
therapy. Clopidogrel bioactivation is dependent on activity
of several cytochrome P450 (CYP) isoenzymes.1,21 In
particular, variation in CYP 2C19 isoenzyme activity due
to common single nucleotide polymorphisms significantly
affects clopidogrel response and on treatment platelet
reactivity.22 Several studies have demonstrated
a reduction of net-MACE events by using pharmacoge-
netics guidance to tailor treatment with clopidogrel after
PCI.18,23-25 On treatment platelet reactivity to ADP by VN
correlates with active clopidogrel metabolite concentration
and is an established pharmacodynamic measure of clopi-
dogrel response.7 Thus, the use of VN assay to screen for
HPR may be an alternative to a pharmacogenetic guided
Table 2 Clinical Events
Clinical Events (1-Year) VerifyNow
Done
No
VerifyNow
Done
Adj. Hazard Ratio (95%
Confidence Interval)
p-value*
Net-MACE (combined death, myocardial infarction, stent
thrombosis, BARC 2 or more bleeding)
19/252 (7.5%) 59/749 (7.9%) 0.92 (0.54–1.5) 0.74
Cardiovascular death 4/252 (1.6%) 14/749 (1.9%) 0.91 (0.29–2.9) 0.87
Myocardial infarction 14/252 (5.6%) 35/749 (4.7%) 1.31 (0.67–2.7) 0.42
BARC 2 or more bleeding 6/252 (2.4%) 14/749 (1.9%) 1.28 (0.49–3.3) 0.61
Note: *Cox proportional hazards model analysis with forward multivariate adjustment of clinically significant baseline co-variates (p<0.1).
Abbreviation: BARC, Bleeding in Academic Research Consortium.
A B
C D
65.0=p:knargoL78.0=p:knargoL
Log rank: p=0.78 Log rank: p=0.56
Figure 2 Clinical outcomes with Kaplan Meier cumulative survival curves for combined primary endpoint (Net-MACE: death, myocardial infarction, stent thrombosis,
bleeding in Academic Research Consortium (BARC) 2 or more) (Panel [A]), myocardial infarction (Panel [B]), cardiovascular death (Panel [C]), and BARC 2 or more
bleeding (Panel [D]). Analysis by log-rank model.
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P2Y12 treatment strategy, and preferable in certain situa-
tions due to the ability to use the VN assay at the point-of-
care with a very short turn-around time. In our study, there
was no significant difference in occurrence of net-MACE
or thrombotic events between groups post PCI, despite
a higher prevalence of ACS in the VN guided group.
Limitations of our study include the retrospective, sin-
gle center design of the study with a limited number of
prescribers, and differences in baseline variables between
patients with and without VN testing. The study was also
not powered to evaluate clinical endpoints.
Conclusions
Tailoring of antiplatelet therapy by VN P2Y12 assay is feasi-
ble, and results in a lower likelihood of using a potent P2Y12
inhibitor post PCI in clinical practice. There was no significant
association of VN P2Y12 assay use with clinical outcomes.
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